Magnetar Financial LLC Takes $337,000 Position in Twist Bioscience Co. (NASDAQ:TWST)

Magnetar Financial LLC acquired a new position in shares of Twist Bioscience Co. (NASDAQ:TWST - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 7,246 shares of the company's stock, valued at approximately $337,000.

A number of other hedge funds have also recently added to or reduced their stakes in TWST. Van ECK Associates Corp raised its stake in Twist Bioscience by 56.4% during the fourth quarter. Van ECK Associates Corp now owns 740 shares of the company's stock worth $34,000 after acquiring an additional 267 shares during the period. Wilmington Savings Fund Society FSB bought a new position in Twist Bioscience during the 3rd quarter worth $34,000. US Bancorp DE increased its holdings in shares of Twist Bioscience by 72.0% in the 4th quarter. US Bancorp DE now owns 1,436 shares of the company's stock worth $67,000 after acquiring an additional 601 shares during the period. Beaird Harris Wealth Management LLC bought a new stake in Twist Bioscience in the 3rd quarter valued at about $95,000. Finally, KBC Group NV boosted its stake in Twist Bioscience by 71.4% during the 4th quarter. KBC Group NV now owns 2,942 shares of the company's stock valued at $137,000 after purchasing an additional 1,226 shares during the period.

Twist Bioscience Price Performance

NASDAQ:TWST traded down $0.30 during trading hours on Thursday, reaching $41.58. 643,757 shares of the company's stock were exchanged, compared to its average volume of 924,398. The company has a quick ratio of 4.62, a current ratio of 4.96 and a debt-to-equity ratio of 0.03. The company has a market capitalization of $2.48 billion, a P/E ratio of -12.30 and a beta of 2.15. Twist Bioscience Co. has a 12 month low of $27.41 and a 12 month high of $60.90. The business's 50-day simple moving average is $45.38 and its two-hundred day simple moving average is $45.34.

Remove Ads

Twist Bioscience (NASDAQ:TWST - Get Free Report) last released its quarterly earnings results on Monday, February 3rd. The company reported ($0.53) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.62) by $0.09. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. The business had revenue of $88.70 million for the quarter, compared to analyst estimates of $86.96 million. During the same quarter in the previous year, the business earned ($0.75) earnings per share. The firm's revenue was up 24.1% compared to the same quarter last year. Sell-side analysts expect that Twist Bioscience Co. will post -2.12 EPS for the current fiscal year.

Insider Transactions at Twist Bioscience

In related news, Director Robert Chess sold 5,000 shares of the stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $50.00, for a total value of $250,000.00. Following the completion of the sale, the director now directly owns 16,641 shares of the company's stock, valued at approximately $832,050. This represents a 23.10 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Adam Laponis sold 5,886 shares of the company's stock in a transaction dated Friday, January 10th. The shares were sold at an average price of $43.26, for a total value of $254,628.36. Following the completion of the transaction, the chief financial officer now owns 110,096 shares in the company, valued at $4,762,752.96. This represents a 5.07 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 33,799 shares of company stock valued at $1,593,944 over the last quarter. Company insiders own 3.01% of the company's stock.

Wall Street Analyst Weigh In

TWST has been the topic of several analyst reports. Wolfe Research began coverage on shares of Twist Bioscience in a research note on Friday, December 13th. They issued an "outperform" rating and a $60.00 price target on the stock. JPMorgan Chase & Co. raised their target price on Twist Bioscience from $35.00 to $40.00 and gave the company an "underweight" rating in a research report on Tuesday, February 4th. Scotiabank reiterated an "outperform" rating on shares of Twist Bioscience in a research report on Tuesday, February 4th. Barclays set a $58.00 price target on Twist Bioscience and gave the company an "overweight" rating in a report on Monday, February 3rd. Finally, Robert W. Baird upped their price objective on shares of Twist Bioscience from $48.00 to $54.00 and gave the stock an "outperform" rating in a report on Tuesday, February 4th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $54.40.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.